ACEi and ARBs as Primary Prevention of Cancer Therapy-Related Cardiomyopathy in Patients Undergoing Chemotherapy with Anthracyclines: A Systematic Review and Meta-Analysis

Abstract Introduction Anthracyclines treat a myriad of malignancies; however, they are known to lead to cancer therapy-related cardiomyopathy (CTRC). Randomized controlled trials (RCTs) evaluating the role of angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) in...

Full description

Bibliographic Details

Published in:	Cardiology and Therapy
Main Authors:	Wissam Harmouch, Ravi Thakker, Alexander Dang, Abdelazeem Mohamed Etewa, Krishna Suthar, Salim Hayek, Wissam Khalife, Ayman Elbadawi
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-03-01
Subjects:	Cancer therapy-related cardiomyopathy Angiotensin converting enzyme inhibitors Angiotensin receptor blockers Ejection fraction Anthracyclines Cardiotoxicity
Online Access:	https://doi.org/10.1007/s40119-025-00401-z